NC 4016

Drug Profile

NC 4016

Alternative Names: DACH-platin micelle - NanoCarrier; DACH-platin polymeric micelle; Debio-0507; NC4016; ND-01

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator NanoCarrier
  • Developer NanoCarrier; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 05 Apr 2016 No development reported - Phase-I for Solid tumours in European Union (IV)
  • 04 Nov 2013 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT01999491)
  • 31 May 2013 NanoCarrier files an IND application with the US FDA for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top